A Novel α9 Integrin Ligand, XCL1/Lymphotactin, Is Involved in the Development of Murine Models of Autoimmune Diseases

• Published in: The Journal of immunology (1950) Vol. 199; no. 1; pp. 82 - 90
• Main Authors: Matsumoto, Naoki, Kon, Shigeyuki, Nakatsuru, Takuya, Miyashita, Tomoe, Inui, Kyosuke, Saitoh, Kodai, Kitai, Yuichi, Muromoto, Ryuta, Kashiwakura, Jun-Ichi, Uede, Toshimitsu, Matsuda, Tadashi
• Format: Journal Article
• Language: English
• Published: United States American Association of Immunologists 01-07-2017
• Subjects: Animal models; Animals; Antibodies, Neutralizing - immunology; Arthritis; Arthritis, Experimental - immunology; Autoimmune diseases; Cell Adhesion; Cell adhesion & migration; Cell Movement; Chemokines, C - immunology; Chemokines, C - metabolism; Collagen (type II); Disease; Disease Models, Animal; Encephalomyelitis; Encephalomyelitis, Autoimmune, Experimental - immunology; Encephalomyelitis, Autoimmune, Experimental - physiopathology; Encephalomyelitis, Autoimmune, Experimental - therapy; Experimental allergic encephalomyelitis; Inflammation; Integrin alpha Chains - immunology; Integrin alpha Chains - metabolism; Leukocyte migration; Ligands; Lymphotactin; Mice; Mice, Inbred C57BL; Migration; Neutralizing; NIH 3T3 Cells; Rhabdomyosarcoma; Rhabdomyosarcoma - immunology; Rodents
• ISSN: 0022-1767; 1550-6606
• DOI: 10.4049/jimmunol.1601329

The integrin α9β1 is a key receptor involved in the development of autoimmune diseases. However, the detailed mechanism for the association of α9β1 integrin with its ligands remains unclear. In this study, we introduce XCL1/lymphotactin, a member of the chemokine family, as a novel ligand for α9 integrin. Using α9 integrin-overexpressing NIH3T3 cells and endogenously α9 integrin-expressing human rhabdomyosarcoma cells, the interaction between XCL1 and α9 integrin was confirmed by pull-down assays. XCL1 enhanced α9 integrin-dependent cell migration of these cells, thus acting on α9 integrin as a chemoattractant. We also analyzed the in vivo function of XCL1 in the development of anti-type II collagen Ab-induced inflammatory arthritis (CAIA) in BALB/c mice and experimental autoimmune encephalomyelitis in C57BL/6 mice, because α9 integrin is involved in these autoimmune disease models. In CAIA, recombinant XCL1 aggravated the disease and this exacerbation was inhibited by an anti-α9 integrin Ab. An XCL1-neutralizing Ab produced in this study also ameliorated CAIA. Furthermore, the XCL1-neutralizing Ab abrogated the disease progression in experimental autoimmune encephalomyelitis. Therefore, to our knowledge this study provides the first in vitro and in vivo evidence that the interaction between XCL1 and α9 integrin has an important role for autoimmune diseases.